Aller au contenu principal
Accès ouvert déclaré 2026 article

Discovery and optimization of a pH-responsive ultra-long-acting VHH-based growth hormone mimetic

0Citations signalées, ce qui n’est pas une note de qualité
0Institutions déclarées
0Pays d’affiliation déclarés

Le résumé fourni par la source

Weekly formulations of long-acting growth hormone (LAGH) effectively treat growth hormone (GH) deficiency in both children and adults while offering improved convenience compared to daily GH. To further enhance patient convenience and compliance, longer-acting GH preparations have become a key research focus. However, due to the inherent short half-life of protein-based drugs, no ultra-long-acting growth hormone or analog products (with dosing intervals longer than once weekly) are currently available worldwide. In this study, we developed a potentially ultra-long-acting growth hormone receptor (GHR) agonist pH.VHH03 with GH-mimetic activity by engineering hinge region and variable region of a VHH antibody. Through optimization of the hinge region, the in vitro cell proliferation activity of this molecule was significantly enhanced. As a result, it demonstrated LAGH-like effects in promoting body weight gain and stimulating IGF-1 secretion in rats. Furthermore, pH-dependent binding was introduced into the variable region. The optimized molecule exhibited a 227-fold difference in dissociation rates between neutral and acidic conditions. This modification prolonged its in vivo efficacy in rats from 6 days to over 15 days, far exceeding the 3-day duration observed with PEGylated GH. Subsequent in vivo experiments in rats confirmed that the final optimized molecule dose-dependently promoted body weight gain, insulin-like growth factor 1 (IGF-1) secretion, tibial growth, and significantly increased growth plate thickness. The in vivo profile fully replicated the physiological activities of GH. Moreover, at medium to high doses, it induced a notably flatter and sustained IGF-1 response compared to PEGylated GH, suggesting a potentially longer duration of pharmacological activities in humans.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Discovery and optimization of a pH-responsive ultra-long-acting VHH-based growth hormone mimetic
Date Crossref
25/06/2026
Éditeur
Informa UK Limited
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les sujets associés

Growth Hormone and Insulin-like Growth FactorsOvarian function and disordersRegulation of Appetite and Obesity

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.